A new step toward individualized antifungal prevention in hematopoietic stem cell transplantation. by Bochud, P.Y. & Calandra, T.
EDITORIAL COMMENTARY • CID 2009:49 (1 September) • 733
E D I T O R I A L C O M M E N T A R Y
A New Step toward Individualized Antifungal Prevention
in Hematopoietic Stem Cell Transplantation
Pierre-Yves Bochud1,2 and Thierry Calandra1
1Department of Internal Medicine, Infectious Diseases Service, and 2Institute of Microbiology, University of Lausanne and Centre Hospitalier Universitaire Vaudois,
Lausanne, Switzerland
(See the article by Plantinga et al on pages 724–32)
Major improvements in our understand-
ing of the innate immune system have
resulted from the discovery of pattern
recognition receptors (PRRs), such as
Toll-like receptors (TLRs), Nod-like re-
ceptors, RIG-I–like receptors, and mem-
bers of the C-type lectins family ex-
pressed by innate immune cells (ie,
monocytes, macrophages, or dendritic
cells) [1]. Strategically located at the in-
terface of host-pathogen interactions,
PRRs play a fundamental role in the sens-
ing of specific microbial molecular pat-
terns and danger signals and in the ini-
tiation of innate and adaptive immune
responses.
The concept of immunogenetics arose
from initial observations, made in the
1940s, that susceptibility to infection was
inheritable [2–4] and from the descrip-
tion, in the 1950s, of the first inheritable
primary immunodeficiencies [5]. More
recently, the availability of high through-
put genotyping techniques has opened
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new perspectives of further improvements
of our understanding of the pathogenesis
of infectious diseases and of new diag-
nostic, preventive, and predictive treat-
ment strategies [6–8].
Polymorphisms of PRRs and down-
stream signaling pathways have been as-
sociated with susceptibility to and out-
come of infection, suggesting that their
detection may have an impact on the pre-
vention or treatment of infectious diseases
[6, 8]. Most striking has been the discovery
of rare inherited immune deficiencies
caused by single, rare polymorphisms in
molecules involved in the TLR signaling
pathways (MyD88, IRAK4, IKKg, and
IkBa) [9–11]. The functional deficiencies
associated with these immunodeficiencies
are usually dramatic and result in clear cut
phenotypes (monogenic inheritance).
Typically, affected offspring develop se-
vere and recurrent infection, caused pre-
dominantly by pyogenic bacteria. These
primary immunodeficiencies clearly il-
lustrate the importance of the TLR-as-
sociated signal transduction pathways in
host innate immune defenses against in-
fection [6–8].
In contrast, susceptibility to infection in
the general population results from poly-
morphisms of several genes, each having
smaller functional contributions (poly-
genic inheritance). Many studies have re-
ported associations between polymor-
phisms of innate immune genes (many
among TLRs) and susceptibility to infec-
tion. However, some of the studies have
also yielded inconclusive or conflicting re-
sults or findings with questionable clinical
implications [6–8]. Several factors may ac-
count for a lack of reproducibility. Two of
the most critical factors have been the use
of imprecise phenotypes of interest and a
lack of power because of small sample
sizes, especially in the case of polymor-
phisms with a modest contribution to the
phenotype under investigation. Other lim-
itations included the failure to account for
important confounders (eg, ethnicity or
the use of inappropriate control subjects
who do not have a similar risk of expo-
sure), inappropriate statistical methods
and analyses (eg, absence of correction for
multiple testing), and the absence of val-
idation cohorts or of functional studies
assessing the in vitro or in vivo biological
impact of the reported polymorphism [6].
Despite all of these potential caveats, some
polymorphisms are now emerging that
have been associated with specific infec-
tions or human diseases. These associa-
tions have been replicated, the functional
consequences of the polymorphisms have
been clearly established, and the poly-
morphism has been shown to have im-
portant implications in the management
of patients.
The interesting report by Plantinga et
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al [12] in this issue of Clinical Infectious
Diseases has focused on the impact of an
early stop codon polymorphism of the
DECTIN-1 gene in hematopoietic stem
cell transplant (HSCT) recipients, which
is a patient population among whom in-
fections cause significant morbidity and
mortality. Dectin-1 is a transmembrane
PRR that specifically recognizes b-1,3-glu-
cans through its extracellular C-type lectin
domain and activates several intracellular
signaling pathways via an intracellular do-
main comprising immunoreceptor tyro-
sine-based activation motifs [13]. Dectin-
1 has been implicated in the recognition
of several fungal pathogens, including
Candida [14], Aspergillus [15], and Pneu-
mocystis species [16]. Upon ligand binding
and in concert with TLR2, dectin-1 ini-
tiates a cascade of intracellular signaling
events that result in cellular immune re-
sponses, including phagocytosis, endocy-
tosis, and the production of chemokines
and cytokines [14, 17]. In a preliminary
study, the authors described an A to T
substitution resulting in a stop codon at
amino acid position 238 of DECTIN-1
(Y238X). This polymorphism has a minor
allele frequency of 6.9% in the Dutch pop-
ulation. It was first identified in a family
in which several members had recurrent
mucocutaneous fungal infections.
In the present article, Plantinga et al
[12] observed an absence of dectin-1 ex-
pression at the monocyte cell surface in
individuals who were homozygous for the
Y238X polymorphism and a much-re-
duced interleukin (IL)–1b production by
peripheral blood mononuclear cells in re-
sponse to stimulation with either heat-
killed Candida species or a combination
of b-glucan and Pam3Cys (a TLR2 acti-
vator), compared with that for wild-type
cells. Data on IL-18 production were less
clear-cut than those on IL-1 production
and were also somewhat surprising, given
that heterozygous cells, compared with
homozygous cells, were associated with a
more pronounced reduction in IL-18 pro-
duction. Of interest, the presence of the
Y238X DECTIN-1 polymorphism, found
in 13 of 124 assessable Dutch patients who
underwent HSCT from human leukocyte
antigen–identical siblings, was associated
with an increased risk of colonization with
Candida species (84.6% vs 31.5%). A rel-
atively small sample size, after exclusion
of those patients who received antifungal
fluconazole prophylaxis, did not allow the
study to examine with sufficient power
whether the polymorphism was also as-
sociated with an increased risk of early
candidemia (ie, occurring on or before day
21), which occurred in 18.2% of the pa-
tients with and 8.0% of the patients with-
out the Y238X polymorphism ( ).Pp .26
Likewise, the study was underpowered to
detect any impact of the DECTIN-1 poly-
morphism on the incidence of mold
infection.
Although one might have wished to be
provided with additional information
about Candida colonization (ie, site and
amount of Candida isolated) and about
potential confounding factors, including
ethnicity, previous antibiotic exposure,
polymorphisms of other PRRs shown to
be implicated in the sensing of Candida
species (for example, TLR2 and TLR4),
and validation of the findings in another
cohort of HSCT recipients, this clinical
observation is strengthened by functional
assessment of the impact of the Y238X
polymorphism on the responses of in-
nate immune cells to Candida species or
b-glucan.
The search for risk factors that predis-
pose to infection remains a major chal-
lenge in treating immunocompetent hosts.
Yet, encouraging progress has been made
recently in the identification of genetic
factors that are implicated in the devel-
opment of opportunistic infections in
immunocompromised patients, includ-
ing those undergoing HSCT or solid-or-
gan transplantation. Several recent stud-
ies have shown the importance of genetic
polymorphisms of TLR4 [18, 19], IL-10
[20, 21], or of the plasminogen gene [22]
in increasing the susceptibility of im-
munosuppressed patients to fungal in-
fection. Somewhat paradoxically, im-
munosuppression did not mask but fa-
cilitated the identification of polymor-
phic alleles that may not have been found
to be relevant otherwise. Patients under-
going treatment with novel immuno-
suppressive drugs, such as anti–tumor
necrosis factor agents, constitute another
rapidly growing population at risk for se-
vere fungal infections [23]. The study by
Plantinga et al [12], linking Y238X poly-
morphism of DECTIN-1 with Candida
colonization, provides a new genetic tar-
get for future epidemiological studies, bi-
ological investigations, and risk stratifi-
cation and is a new step forward toward
improved predictive and preventive med-
icine for immunocompromised hosts.
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